Big drug companies have been buying scrappy biotechs to expand their pipelines, but the potential megamerger between AstraZeneca and Bristol Myers Squibb could flip that script.

Why it matters: Combining two drug giants with overlapping portfolios could put cost efficiencies ahead of innovation.

• It could also revive the late 1990s/early 2000s belief that big mergers are the ticket to sustained earnings growth.

The big picture: A Sunday FT report that the companies were exploring a tie-up to create a $400 billion drug behemoth left a lot of unanswered questions about how they'll manage their overlapping pipelines and consolidate sprawling operations.

• The deal would combine U.K.-based AstraZeneca's powerhouse oncology portfolio with BMS' leading immunology franchise and other established medicines.
• But it could force difficult trade-offs as the companies combine pipelines and manufacturing while navigating possible antitrust concerns.
• "It reopens the door to those sort of scale-driven acquisitions that pharma doesn't really do that often," said Beth Snyder Bulik, senior analyst at eMarketer.

Between the lines: Megamergers promise billions in efficiencies — including the possibility of layoffs. One of the most recent was BMS' deal to buy Celgene in 2019.

• An AstraZeneca deal could force the combined companies to mash overlapping pipelines, kill off duplicative research or lower-priority projects and squeeze R&D in the name of cost savings.
• It could also shift interest away from acquiring smaller companies with one or two promising treatments in development, analysts said.
• "A deal of this size would significant[ly] limit additional near-term business development, which therefore can negatively impact the biotech ecosystem," said Matt Phipps, a partner with William Blair.

Wall Street generally reacted with skepticism, and AstraZeneca shares were down almost 7% Monday.

• "We don't see logic in combination of AZN and BMY," TD Cowen wrote in a note to investors. It's "more than a head scratcher," wrote Jefferies analyst Michael Leuchten.

Keep reading

A group of government workers sued the Trump administration yesterday over its policy of prohibiting coverage for gender-affirming care through the federal employee and U.S. Postal Service health plans.

Why it matters: The complaint is the latest pushback against a widening crackdown on transition-related care that's included subpoenas of providers and threats to hospitals' federal funding.

Driving the news: The lawsuit, filed by the Human Rights Campaign Foundation and the law firm Correia & Puth, charges the administration violated civil rights law by discriminating against federal employees on the basis of sex.

• It cites a transgender State Department employee, identified with a pseuydonym, who faces over $100,000 in out-of-pocket costs for transition-related surgery as a result of the policy.
• An HHS employee without coverage faces costs of approximately $1,000 per year for hormone-replacement therapy and about $6,000 for gender-affirming surgery, per the lawsuit.
• The Human Rights Campaign Foundation cited a UCLA study that found the coverage exclusion will impact health access for at least 39,400 current and former federal employees and their dependents.

Between the lines: The Office of Personnel Management last August issued a directive barring coverage of transition-related hormone treatments and surgeries for the plan year 2026.

• While it carved out an exception for beneficiaries who are "mid-treatment" for diagnosed gender dysphoria, it didn't define that term or identify criteria insurers could use to determine whether a beneficiary qualifies, according to the Human Rights Campaign Foundation.

Two people in Michigan have died in connection with the multistate cyclosporiasis outbreak, Michigan health officials said yesterday, marking the first known deaths linked to the outbreak.

Why it matters: Weeks into the national crisis that's sickened thousands of people, federal authorities still don't know for certain where it's coming from or why.

Driving the news: Medical records show that the individuals who died "had significant underlying health conditions that may have been impacted by cyclosporiasis and dehydration," Michigan's Health and Human Services Department said yesterday.

• Generally, health experts don't consider cyclosporiasis to be life-threatening.

Catch up quick: Cyclospora cases have steadily grown since late June, when an outbreak was reported in Michigan.

• The CDC is aware of more than 11,000 cases nationwide — though the number is likely much higher as not all cases are reported to state health officials or the CDC.

Context: Health officials still don't know where the outbreak originated, though many cases were linked to fresh produce from Taylor Farms, which is sold at Taco Bell.

• Taylor Farms recalled iceberg lettuce sourced from Mexico in mid-July over the outbreak. Taco Bell similarly said it would stop serving Taylor Farms lettuce.

🔬 A Senate bill to fund the government through Dec. 11 would block a controversial proposal to give political appointees control over which research grants get funded. (Scientific American)

⚕️ At the San Diego-Tijuana border, syphilis spreads while researchers contend with federal constraints and a drug shortage. (Stat)

🤖 Getting AI out of the chat box and into the physical world has been a major focus for investors and developers. The road runs directly through the elder care market. (PitchBook)